| Aspirin and other antiplatelet drugs in the prophylaxis of thrombosis. | |
| | |
MedLine Citation:
|
PMID: 3332089 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Aspirin is of proven value as an antithrombotic drug. In unstable angina it reduces the risk of death and myocardial infarction by half. After a myocardial infarction it reduces the risk of death by about 10% and of coronary incidence (coronary death or definite myocardial infarction) by about 25%. These effects appear to be additive with those of beta-blocking drugs. Aspirin also reduces the risk of occlusion of aortocoronary saphenous vein grafts by about half. In transient cerebral ischaemia, aspirin may reduce the risk of stroke and death by 50%. In most clinical trials to date the daily dose of aspirin ranges from 325 mg to 1400 mg. Interest in very low doses of aspirin (less than 60 mg daily) is considerable but has yet to be translated into proven clinical benefit. Dipyridamole has not been shown to be effective as an antithrombotic when used alone. Its antiplatelet action ex vivo may be enhanced by combination with aspirin but clinical trials have shown relatively little advantage of the combination over aspirin alone. Sulphinpyrazone has not become established as a first line antithrombotic drug. Epoprostenol is useful in extracorporeal circulations to prevent platelet consumption and possibly in severe inoperable peripheral vascular disease. |
| | |
Authors:
|
J Webster; A S Douglas |
Related Documents
:
|
9589829 - Antiplatelet therapy in atherosclerotic cardiovascular disease. 8419269 - The role of dipyridamole in the therapy of vascular disease. 946309 - Selective coronary arteriography. risk in a community hospital. 9462569 - High dose bolus heparin as initial therapy before primary angioplasty for acute myocard... 10639269 - The essence trial: efficacy and safety of subcutaneous enoxaparin in unstable angina an... 10709819 - Reduction of blood loss and transfusion requirements after coronary artery bypass graft... 1429129 - Postsurgical ventricular tachycardia in a horse. 21392599 - Integrating the synergy between percutaneous coronary intervention with taxus and cardi... 21461359 - Usefulness of hemodynamic sensors for physiologic cardiac pacing in heart failure patie... |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Review |
Journal Detail:
|
Title: Blood reviews Volume: 1 ISSN: 0268-960X ISO Abbreviation: Blood Rev. Publication Date: 1987 Mar |
Date Detail:
|
Created Date: 1988-11-23 Completed Date: 1988-11-23 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 8708558 Medline TA: Blood Rev Country: SCOTLAND |
Other Details:
|
Languages: eng Pagination: 9-20 Citation Subset: IM |
Affiliation:
|
Department of Medicine and Therapeutics, University of Aberdeen. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aspirin
/
therapeutic use* Clinical Trials as Topic Coronary Disease / prevention & control* Coronary Thrombosis / prevention & control* Humans Platelet Aggregation Inhibitors / therapeutic use* |
| Chemical | |
Reg. No./Substance:
|
0/Platelet Aggregation Inhibitors; 50-78-2/Aspirin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The value of indium-labelled leucocytes in clinical practice.
Next Document: The role of pentostatin (2'-deoxycoformycin, dCF) in the management of lymphoproliferative malignanc...